Correction: ISG15 is counteracted by vaccinia virus E3 protein and controls the proinflammatory response against viral infection [Journal of Virology, 88, 4, (2014) (2312-2318)]doi 10.1128/JVI.03293-13;ISG15 is counteracted by vaccinia virus E3 protein and controls the proinflammatory response against viral infection

Journal of Virology

Volumn 88, Issue 4, 2014, Pages 2312-2318

  Eduardo Correia, Benedito ^a   Martínez Romero, Carles ^b   García Sastre, Adolfo ^b   Guerra, Susana ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; PROTEIN ISG15; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FIBROBLAST; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; VACCINIA VIRUS;

ANIMALS; CYTOKINES; HISTOLOGICAL TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MUTATION; PEPTIDE HYDROLASES; POXVIRIDAE INFECTIONS; RNA-BINDING PROTEINS; UBIQUITINS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84893471553     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01920-16     Document Type: Erratum

References (38)

1. Diamond MS, Farzan M. 2013. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat. Rev. Immunol. 13:46-57. http://dx.doi.org/10.1038/nri3344.
2. Au WC, Moore PA, Lowther W, Juang YT, Pitha PM. 1995. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc. Natl. Acad. Sci. U.S.A. 92:11657-11661. http://dx.doi.org/10.1073/pnas.92.25.11657.
3. Austin KJ, Bany BM, Belden EL, Rempel LA, Cross JC, Hansen TR. 2003. Interferon-stimulated gene-15 (Isg15) expression is up-regulated in the mouse uterus in response to the implanting conceptus. Endocrinology 144:3107-3113. http://dx.doi.org/10.1210/en.2002-0031.
4. Liu YC, Penninger J, Karin M. 2005. Immunity by ubiquitylation: a reversible process of modification. Nat. Rev. Immunol. 5:941-952. http://dx.doi.org/10.1038/nri1731.
5. Dastur A, Beaudenon S, Kelley M, Krug RM, Huibregtse JM. 2006. Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J. Biol. Chem. 281:4334-4338. http://dx.doi.org/10.1074/jbc.M512830200.
6. Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, Schulman BA, Huibregtse JM, Krug RM. 2004. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc. Natl. Acad. Sci. U.S.A. 101:7578-7582. http://dx.doi.org/10.1073/pnas.0402528101.
7. Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, Kim KI, Peterson LF, Shuai K, Zhang DE. 2003. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev. 17:455-460. http://dx.doi.org/10.1101/gad.1056303.
8. Zou W, Papov V, Malakhova O, Kim KI, Dao C, Li J, Zhang DE. 2005. ISG15 modification of ubiquitin E2 Ubc13 disrupts its ability to form thioester bond with ubiquitin. Biochem. Biophys. Res. Commun. 336:61-68. http://dx.doi.org/10.1016/j.bbrc.2005.08.038.
9. Lu G, Reinert JT, Pitha-Rowe I, Okumura A, Kellum M, Knobeloch KP, Hassel B, Pitha PM. 2006. ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. Cell. Mol. Biol. (Noisy-le-Grand) 52: 29-41.
10. Kim MJ, Hwang SY, Imaizumi T, Yoo JY. 2008. Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. J. Virol. 82:1474-1483. http://dx.doi.org/10.1128/JVI.01650-07.
11. Minakawa M, Sone T, Takeuchi T, Yokosawa H. 2008. Regulation of the nuclear factor (NF)-kappaB pathway by ISGylation. Biol. Pharm. Bull. 31:2223-2227. http://dx.doi.org/10.1248/bpb.31.2223.
12. Werneke SW, Schilte C, Rohatgi A, Monte KJ, Michault A, Arenzana-Seisdedos F, Vanlandingham DL, Higgs S, Fontanet A, Albert ML, Lenschow DJ. 2011. ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation. PLoS Pathog. 7:e1002322. http://dx.doi.org/10.1371/journal.ppat.1002322.
13. Lenschow DJ. 2010. Antiviral properties of ISG15. Viruses 2:2154-2168. http://dx.doi.org/10.3390/v2102154.
14. Skaug B, Chen ZJ. 2010. Emerging role of ISG15 in antiviral immunity. Cell 143:187-190. http://dx.doi.org/10.1016/j.cell.2010.09.033.
15. Lenschow DJ, Giannakopoulos NV, Gunn LJ, Johnston C, O'Guin AK, Schmidt RE, Levine B, and Virgin HW, IV. 2005. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J. Virol. 79:13974-13983. http://dx.doi.org/10.1128/JVI.79.22.13974-13983.2005.
16. Malakhova OA, Zhang DE. 2008. ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J. Biol. Chem. 283: 8783-8787. http://dx.doi.org/10.1074/jbc.C800030200.
17. Okumura A, Pitha PM, Harty RN. 2008. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc. Natl. Acad. Sci. U.S.A. 105:3974-3979. http://dx.doi.org/10.1073/pnas.0710629105.
18. Guerra S, Lopez-Fernandez LA, Conde R, Pascual-Montano A, Harshman K, Esteban M. 2004. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J. Virol. 78:5820-5834. http://dx.doi.org/10.1128/JVI.78.11.5820-5834.2004.
19. Guerra S, Lopez-Fernandez LA, Pascual-Montano A, Munoz M, Harshman K, Esteban M. 2003. Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J. Virol. 77:6493-6506. http://dx.doi.org/10.1128/JVI.77.11.6493-6506.2003.
20. Guerra S, Lopez-Fernandez LA, Pascual-Montano A, Najera JL, Zaballos A, Esteban M. 2006. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells. J. Virol. 80:985-998. http://dx.doi.org/10.1128/JVI.80.2.985-998.2006.
21. Guerra S, Caceres A, Knobeloch KP, Horak I, Esteban M. 2008. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog. 4:e1000096. http://dx.doi.org/10.1371/journal.ppat.1000096.
22. Rivas C, Gil J, Melkova Z, Esteban M, Diaz-Guerra M. 1998. Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology 243:406-414. http://dx.doi.org/10.1006/viro.1998.9072.
23. Wreschner DH, Silverman RH, James TC, Gilbert CS, Kerr IM. 1982. Affinity labelling and characterization of the ppp(A2'p)nA-dependent endoribonuclease from different mammalian sources. Eur. J. Biochem. 124: 261-268.
24. Smith EJ, Marie I, Prakash A, Garcia-Sastre A, Levy DE. 2001. IRF3 and IRF7 phosphorylation in virus-infected cells does not require doublestranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein. J. Biol. Chem. 276:8951-8957. http://dx.doi.org/10.1074/jbc.M008717200.
25. Xiang Y, Condit RC, Vijaysri S, Jacobs B, Williams BR, Silverman RH. 2002. Blockade of interferon induction and action by the E3L doublestranded RNA binding proteins of vaccinia virus. J. Virol. 76:5251-5259. http://dx.doi.org/10.1128/JVI.76.10.5251-5259.2002.
26. Deng L, Dai P, Ding W, Granstein RD, Shuman S. 2006. Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells. J. Virol. 80:9977-9987. http://dx.doi.org/10.1128/JVI.00354-06.
27. Sridharan H, Zhao C, Krug RM. 2010. Species specificity of the NS1 protein of influenza B virus: NS1 binds only human and non-human primate ubiquitin-like ISG15 proteins. J. Biol. Chem. 285:7852-7856. http://dx.doi.org/10.1074/jbc.C109.095703.
28. Versteeg GA, Hale BG, van Boheemen S, Wolff T, Lenschow DJ, Garcia-Sastre A. 2010. Species-specific antagonism of host ISGylation by the influenza B virus NS1 protein. J. Virol. 84:5423-5430. http://dx.doi.org/10.1128/JVI.02395-09.
29. Guerra S, Abaitua F, Martinez-Sobrido L, Esteban M, Garcia-Sastre A, Rodriguez D. 2011. Host-range restriction of vaccinia virus E3L deletion mutant can be overcome in vitro, but not in vivo, by expression of the influenza virus NS1 protein. PLoS One 6:e28677. http://dx.doi.org/10.1371/journal.pone.0028677.
30. Chang HW, Jacobs BL. 1993. Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to doublestranded RNA. Virology 194:537-547. http://dx.doi.org/10.1006/viro.1993.1292.
31. Kim YG, Muralinath M, Brandt T, Pearcy M, Hauns K, Lowenhaupt K, Jacobs BL, Rich A. 2003. A role for Z-DNA binding in vaccinia virus pathogenesis. Proc. Natl. Acad. Sci. U.S.A. 100:6974-6979. http://dx.doi.org/10.1073/pnas.0431131100.
32. Langland JO, Jacobs BL. 2004. Inhibition of PKR by vaccinia virus: role of the N-and C-terminal domains of E3L. Virology 324:419-429. http://dx.doi.org/10.1016/j.virol.2004.03.012.
33. Beattie E, Kauffman EB, Martinez H, Perkus ME, Jacobs BL, Paoletti E, Tartaglia J. 1996. Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes 12:89-94. http://dx.doi.org/10.1007/BF00370005.
34. Yin C, Khan JA, Swapna GV, Ertekin A, Krug RM, Tong L, Montelione GT. 2007. Conserved surface features form the double-stranded RNA binding site of non-structural protein 1 (NS1) from influenza A and B viruses. J. Biol. Chem. 282:20584-20592. http://dx.doi.org/10.1074/jbc.M611619200.
35. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, Wolff T, Osiak A, Levine B, Schmidt RE, Garcia-Sastre A, Leib DA, Pekosz A, Knobeloch KP, Horak I, Virgin HW, IV. 2007. IFNstimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl. Acad. Sci. U.S.A. 104:1371-1376. http://dx.doi.org/10.1073/pnas.0607038104.
36. Frias-Staheli N, Giannakopoulos NV, Kikkert M, Taylor SL, Bridgen A, Paragas J, Richt JA, Rowland RR, Schmaljohn CS, Lenschow DJ, Snijder EJ, Garcia-Sastre A, Virgin HW, IV. 2007. Ovarian tumor domaincontaining viral proteases evade ubiquitin-and ISG15-dependent innate immune responses. Cell Host Microbe 2:404-416. http://dx.doi.org/10.1016/j.chom.2007.09.014.
37. Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D, Salem S, Radovanovic I, Grant AV, Adimi P, Mansouri N, Okada S, Bryant VL, Kong XF, Kreins A, Velez MM, Boisson B, Khalilzadeh S, Ozcelik U, Darazam IA, Schoggins JW, Rice CM, Al-Muhsen S, Behr M, Vogt G, Puel A, Bustamante J, Gros P, Huibregtse JM, Abel L, Boisson-Dupuis S, Casanova JL. 2012. Mycobacterial disease and impaired IFNgamma immunity in humans with inherited ISG15 deficiency. Science 337:1684-1688. http://dx.doi.org/10.1126/science.1224026.
38. Yanguez E, Garcia-Culebras A, Frau A, Llompart C, Knobeloch KP, Gutierrez-Erlandsson S, Garcia-Sastre A, Esteban M, Nieto A, Guerra S. 2013. ISG15 regulates peritoneal macrophages functionality against viral infection. PLoS Pathog. 9:e1003632. http://dx.doi.org/10.1371/journal.ppat.1003632.